

National Pharmaceutical Pricing Authority

Subject: Minutes of the 52nd meeting of the Multidisciplinary Committee of Experts held on 11.07.2023 at 12:00 Noon.

52nd meeting of the "Multidisciplinary Committee of Experts" was held on 11.07.2023 at 12:00 Noon under the convenorship of Shri Sanjay Kumar, Advisor (Cost). The following members attended the meeting: -

1. Shri A.K. Pradhan, Jt. Drugs Controller, CDSCO through Video Conferencing
2. Dr. Rakesh Kr. Singh, Associate Professor, NIPER Raebareli through Video Conferencing
3. Prof. Y. K. Gupta, Principal Scientific Advisor (Projects), THSTI-DBT, GoI & Ex-HoD, Pharmacology & Dean (Academics), AIIMS, New Delhi - Co-opted member through Video Conferencing
4. Dr. Pooja Gupta, Associate Professor, Department of Pharmacology, AIIMS- New Delhi through Video Conferencing
5. Dr. Jai Prakash, Sr. Principal Scientific Officer, Indian Pharmacopoeia Commission - Co-opted member through video conferencing

The following officers of NPPA attended and presented the cases before the Committee

- a. Ms. Rashmi Tahiliani, Jt. Director (Pricing)
- b. Shri Mahaveer Saini, Deputy Director (Pricing), NPPA

Agenda Item No. 1: Retail price fixation under DPCO, 2013 - Each film coated tablet contains: Azelnidipine IP 16mg + Telmisartan IP 40mg for M/s Akums Drugs & Pharmaceuticals Ltd. (Manufacturer) and M/s Ipca Laboratories Limited (Marketer)(F.N.3446) at Rs. 1.89 per tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price is as below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each film coated tablet contains: Azelnidipine IP 16mg + Telmisartan IP 40mg		
(a)	Telmisartan IR 40 mg	Ceiling Price as applicable six months prior to month in	7.32

		which application is received [SO. 1499(E) dated 30.03.2022]	
(b)	Calculated retail price of Azelnidipine IP 16 mg tablet	Retail price (as per October, 2022 data)	12.10
(c)	Total (a+b)		19.42
(d)	Less 20% of the lower of (a) or (b)		1.46
(e)	Worked out Retail Price (c)-(d)		17.96
(f)	Claimed Retail price		1.89
	Recommended Price (Lower of worked out and claimed price) per tablet		1.89

Agenda Item No. 2. Retail price fixation under DPCO, 2013- Each Sachet of 4.40g contains: Zinc Sulphate Monohydrate IP 0.011g + Sodium Citrate IP 0.58g + Potassium Chloride IP 0.30g + Sodium Chloride IP 0.52g + Dextrose Anhydrous IP 2.70g for M/s Acme Diet care Pvt. Ltd. (manufacturer) and M/s Alkem Laboratories Limited (marketer) (F.No. 3468) at Rs. 6.12 per Sachet of 4.40gm excluding GST.

1. The committee deliberated on the matter and recommended retail price is as below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each Sachet of 4.4g contains: Zinc Sulphate Monohydrate IP 0.011g + Sodium Citrate IP 0.58g + Potassium Chloride IP 0.30g + Sodium Chloride IP 0.52g + Dextrose Anhydrous IP 2.70g		
(a)	Calculated retail price of Zinc Sulphate Monohydrate IP 0.011g	Note 1	2.23
(b)	Sodium Citrate IP 0.58g + Potassium Chloride IP 0.30g + Sodium Chloride IP 0.52g + Dextrose Anhydrous IP 2.70g (ORS Sachet)	Ceiling Prices of ORS Sachet as applicable 6 months prior to the month of application(as per Notification No. 1499(E) dated 30.03.2022i. e Rs.0.99 per GM)	4.33

(c)	Less 20% of the lower of (a) and (b)		0.44
(d)	Worked out Retail Price (a)+(b)-(c)		6.12
(e)	Claimed Retail price		7.14
	Recommended retail price (Lower of worked out & claimed price)per Sachet of 4.40g		6.12

Note 1: Calculation of Retail Price of Zinc Sulphate Monohydrate IP 0.011g powder Ceiling Price of Zinc Sulphate Dispersible Tablet 20 mg applicable 6 months prior to date of application= Rs 3.49 per tablet. (as per Notification No. 1499(E) dated 30.03.2022)

Therefore, the derived Retail Price for Zinc Sulphate Monohydrate IP 0.011 g or 11 mg = Derived retail price as per recommendation of Pronab Sen committee:

$$P(s) = P^*[1+a.\{(s-s^*)/s^*\}]$$

Where: P(s) =Price ceiling of the strength

P* = price ceiling for reference strength

s = strength in terms of API content

s* = reference strength

a= 0.8 for tablet / capsule and 0.7 for injectables

Accordingly, the committee recommended Retail Price for Zinc Sulphate Monohydrate IP 0.011 g or 11 mg as below by applying the Pronab Sen Formula to Zinc Sulphate Dispersible Tablet 20 mg:

$$= 3.49[1+0.8\{(11-20)/20\}] = \text{Rs. } 2.23 \text{ (excluding GST)}$$

Agenda Item No. 3. Retail price fixation of each 5ml of reconstituted suspension contains: Cefixime IP (As Trihydrate) eq. to Anhydrous Cefixime 200mg for M/s Alkem Healthscience (Manufacturer) and M/s Alkem Laboratories Limited (Marketer) under DPCO, 2013 (F.No. 3455 & 3456)at Rs. 4.06 per ML excluding GST.

1. The committee noted that two separate applications have been filed i.e. for pack of 30 ml and for pack of 60ml by the applicant. The committee deliberated upon the matter and recommended retail price on per ml basis as below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each 5ml of reconstituted suspension contains: Cefixime IP (As Trihydrate) eq. to Anhydrous Cefixime 200mg		
(a)	Derived retail price of Anhydrous Cefixime 200mg	Retail price (as per the formula of Pranob Sen Committee) [Note-1]	4.06
(b)	Claimed Retail price		

(i) For 30ml pack size - Rs. 175 per pack (Including GST) i.e. Rs. 5.21/- per ml (Excluding GST)	5.21
(ii) For 60ml pack size - Rs. 300 per pack (Including GST) i.e. Rs. 4.46/- per ml (Excluding GST)	4.46
Recommended retail price per ml (Lower of worked out & claimed price)	4.06

Note-1

The retail price of Cefixime IP (As Trihydrate) eq. to Anhydrous cefixime 200 mg has been calculated as per the formula recommended in the Pronab Sen Committee report. The calculation is as below: -

Derived retail price as per recommendation of Pronab Sen committee:

$$P(s) = P*[1+a.\{(s-s^*)/s^*\}]$$

Where: P(s) = Price ceiling of the strength s

P* = price ceiling for reference strength s*

s = strength in terms of API content

s* = reference strength

a = 0.8 for tablet / capsule and 0.7 for injectibles.

Ceiling price of Cefixime Oral liquid 100mg/5mL (p) as on November, 2022 = Rs. 2.39 per ml excluding GST [S.O. No. 1499(E) dated 30.03.2022]

Accordingly, the committee recommended as below by applying the Pronab Sen Formula to Cefixime Oral liquid 100mg/5mL:

$$= 2.39[1+0.7\{(200-100)/100\}] = \text{Rs. } 4.06 \text{ (excluding GST)}$$

Agenda Item No. 4. Retail price fixation of Each film coated tablet contains: Telmisartan IP 40mg + Bisoprolol Fumarate IP 2.5mg for M/s Ravenbhel Healthcare Pvt. Ltd. (Manufacturer) and M/s Zuventus Healthcare Limited (Marketer) under DPCO, 2013 (F.N. 3424) at Rs. 11.01 per Tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price is as below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each uncoated bilayered tablet contains: Bisoprolol Fumarate IP 5 mg +Telmisartan IP40mg		
(a)	Telmisartan IR 40 mg	Ceiling Price [SO. 1499(E) dated	7.32

		30.03.2022]as applicable 6 months prior to the month of application	
(b)	Calculated retail price of Bisoprolol Fumarate IP 2.5 mg tablet	Retail price (as per October, 2022 data)	4.61
(c)	Total (a+b)		11.93
(d)	Less 20% of the lower of (a) or (b)		0.92
(e)	Worked out Retail Price (c)-(d)		11.01
(f)	Claimed Retail price		14.00
	Recommended retail price (Lower of worked out & claimed price) per tablet		11.01

Agenda Item No. 5. Retail price fixation of Each film coated tablet contains: Telmisartan IP 40mg + Bisoprolol Fumarate IP 5mg for M/s Ravenbhel Healthcare Pvt. Ltd. (Manufacturer) and M/s Zuventus Healthcare Limited (Marketer) under DPCO, 2013 (F.N. 3425)at Rs. 13.12 per Tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price is as below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each uncoated bilayered tablet contains: Bisoprolol Fumarate IP 5 mg +Telmisartan IP40mg		
(a)	Telmisartan IR 40 mg	Ceiling Price [SO. 1499(E) dated 30.03.2022] as applicable 6 months prior to the month of application	7.32
(b)	Calculated retail price of Bisoprolol Fumarate IP 5 mg tablet	Retail price (as per October, 2022 data)	7.25
(c)	Total		14.57
(d)	Less 20% of the lower of (a) or (b)		1.45
(e)	Worked out Retail Price (c)-(d)		13.12
(f)	Claimed Retail price		16.00
	Recommended retail price (Lower of worked out & claimed price) per tablet		13.12

Agenda Item No. 6: Approval for ceiling price of different dosage forms and strength of I.V Fluids with packaging in non glass with special features "EUROHEAD" dated 24.04.2023 being filed by M/s Aculife Healthcare Pvt. Ltd.

6.1 The applicant company demonstrated it's product Metronidazole injection before the Committee through VC. The committee examined the documents submitted by M/s Aculife

Healthcare Pvt. Ltd and observed that the company had not provided the data relating to flow rate of the fluid. Further, from the documents submitted, it could not be ascertained that the plastic used in packing is as per the IP standards. The Committee deliberated on the matter in detail and directed that the applicant may be requested to provide the following documents:

- i. Flow Rate data showing flow rate at beginning, middle and end.
- ii. Undertaking that the plastic used in manufacturing of the bottle is as per IP Standards and Certificate of Analysis for the same

6.2 After receipt of the above documents, the matter may be placed before the MDC.

Agenda Item No. 7. Approval for ceiling price of different dosage forms and strength of I.V Fluids with packaging in non glass with special features "BIOPORT" dated 05.06.2023 being filed by M/s Biosynergy Lifecare Pvt. Ltd.

7.1 The applicant was asked to demonstrate their product before the committee but due to connectivity problem (participated through VC) demonstration could not be done by the applicant company. Further, the Committee deliberated on the matter and directed that the applicant may be requested for demonstration of it's applied products along with the following additional documents in the next MDC meeting:

- i. Undertaking that the plastic used in manufacturing of the bottle is as per IP Standards and Certificate of Analysis for the same

7.2 After receipt of the above documents, the matter may be placed before the MDC.

Agenda Item No. 8. Application for extension of ceiling price for I.V. Fluid Sodium Chloride 0.9% 100 ml with packing in non-glass with special feature (Euro Head) in line with S.O. No. 1500(E) dt. 30.03.2022 filed M/s Pureto Lifesciences Private Limited

8.1 The applicant informed that they would not be able to demonstrate their products before the committee at short notice and requested to allow the same in next meeting of MDC. Accordingly, the committee directed that the applicant may be requested to demonstrate the applied products in the next meeting of MDC along with the following documents:

- i. Flow Rate data showing flow rate at beginning, middle and end.
- ii. Undertaking that the plastic used in manufacturing of the bottle is as per IP Standards and Certificate of Analysis for the same

8.2 After receipt of the above documents, the matter may be placed before the MDC.

Agenda Item No. 9. Approval for ceiling price of different dosage forms and strength of I.V Fluids with packaging in non glass with special feature notified vide S.O No. 1569 (E), 1570 (E), 1571 (E), 1574 (E), 1576 (E), 1577 (E) dt.31.03.2023 by M/s Promea Therapeutics Pvt. Ltd.



9.1 The Committee examined the documents submitted by the applicant company and observed that no data has been provided in relation to the flow rate. Hence, the committee directed that the applicant company may be requested to give demonstration of its applied products along with the following documents in the next MDC meeting:

- i. Flow Rate data showing flow rate at beginning, middle and end.
- ii. Undertaking that the plastic used in manufacturing of the bottle is as per IP Standards and Certificate of Analysis for the same

9.2 After receipt of the above documents, the matter may be placed before the MDC.

Agenda Item No. 10. Retail Price fixation of formulation "Formoterol Fumarate Dihydrate 6mcg + Beclomethasone Dipropionate IP 100 mcg Inhaler (MDI) for M/s Cipla Limited in view of DoP's Review Order dated 03.10.2022.

10.1 The matter relates to retail price fixation of formulation "Formoterol Fumarate Dihydrate 6mcg + Beclomethasone Dipropionate IP 100 mcg Inhaler (MDI) for M/s Cipla Limited in view of DoP's Review Order dated 03.10.2022.

10.2 The matter was briefed to the committee. The matter was deliberated in the 47th meeting of MDC held on 02.12.2022, wherein company representatives were also present and a fresh hearing on the matter was given to the company. After detailed deliberations, the committee recommended that special pricing on account of improved formulations as claimed by M/s Cipla Limited may be considered for further examination, if the company submits published literature demonstrating the improved efficacy of its product and obtain the manufacturing permission/license from the licensing authorities along with the product label claim. Letter dated 27.12.2022 was sent to M/s Cipla Limited in this respect. M/s Cipla Limited vide letter dated 09.01.2023 requested to allow one month time to submit their response. However, no further reply was received from M/S Cipla Limited.

10.3 The matter was again deliberated in the 49th meeting of MDC held on 23.02.2023, wherein committee was apprised that even till 23.02.2023 requisite information was not received from M/S Cipla. The committee deliberated on the matter and directed that a reminder may be issued to M/s Cipla Limited giving one week time to submit the requisite details and if the same are not received within the due time, the matter shall be treated as closed. Letter dated 10.03.2022 was sent to M/s Cipla seeking the requisite information within one week.

10.4 Accordingly, since no further information was received from the company, the matter was placed before Authority in its 112th meeting held on 01.05.2023 for closure of the matter in line with recommendation of 49th meeting of MDC. The Authority referred back the matter to the MDC for providing clear recommendations in the matter.

10.5 The matter was deliberated by the Committee and it was decided that complete point-wise examination may be placed in the next MDC w.r.t. to issues raised by M/s Cipla Limited before Hon'ble High Court & during the Review, so that MDC may submit its recommendations on the matter.

Agenda Item No. 11. Application by M/s Troikaa Pharmaceuticals Limited for exemption from the provisions of Drug Price Control Order 2013 under Para 32 (i) to (iii) for the formulations "Paracetamol Injection (Intramuscular) 250mg/ml".

11.1 It was briefed to the Committee that the matter relates to exemption under Para 32 (i) to (iii) for the formulations "Paracetamol Injection (Intramuscular) 250mg/ml" applied by M/s Troikaa Pharmaceuticals Limited vide e-mail dated 01.10.2022. The committee in its 50th meeting held on 21.04.2023 deliberated upon the report of the Patent office in detail and observed that M/s Troikaa Pharmaceuticals Ltd. fulfils the conditions of para 32(i) of DPCO, 2013 with respect to the formulation "Paracetamol Injection (Intramuscular) 250mg/ml". Accordingly, the committee recommended that exemption may be granted to M/s Troikaa Pharmaceuticals Ltd. under para 32(i) of DPCO, 2013 with respect to the formulation "Paracetamol Injection (Intramuscular) 250mg/ml".

11.2 The recommendation of the committee was placed in 113th meeting of the Authority held on 26.05.2023, wherein the Authority deliberated on the matter and observed that further clarity is required on the application and the innovation claimed by M/s Troikaa Pharmaceuticals Limited for Paracetamol Injection (Intramuscular) 250mg/ml. Hence, information on following would also be required:

- (a) The company may clearly clarify the exemption sought under which specific section of DPCO, 2013 i.e. 32(i)/32(ii)/32(iii) with reasons.
- (b) Detailed inputs of the Office of DCGI regarding the approval of the said drug.

Authority also noted that on receipt of inputs as stated above, the case may be taken to MDC again for examining the case holistically keeping in view the innovation claimed for the said drug.

11.3 In this regard, it is pertinent to mention herein that before the letter could be sent to M/S Troikaa, the company on the basis of uploaded Minutes of the 113th Authority meeting (uploaded on NPPA website on 8.6.2023) informed that their "product Paracetamol Injection (Intramuscular) 250mg/ml is eligible for exemption under Para 32(i) of DPCO 2013 vide letter dated 16.06.2023. The applicant also submitted the advantages of their novel Paracetamol Injection (Intramuscular) 250mg/ml over conventional Paracetamol injection 300 mg/2ml or 450 mg/3ml available in market. Hence, no letter was sent to the company in this respect. The reply of the company vide the said letter were examined by the committee. Further, letter dated 20.06.2023 was sent to Office of DCGI seeking detailed inputs of the Office of DCGI regarding the approval of the said drug. However, no reply has been received so far. Further, representative of the CDSCO was requested to provide the requisite inputs as to how the product is superior over other paracetamol injections in the market.

11.4. The representative of the CDSCO stated that although Paracetamol Injections are available in the market, but the applicant's formulation can administer higher strength in low volume and deliver the right dose. It has advantage over other available intramuscular injections of Paracetamol. Further, applicant was issued new drug permission after examination of rationality and clinical trial data including Pharmacokinetic in consultation

with Subject Expert Committee. Representative of the DCGI also mentioned that details of the same would be sent to NPPA shortly.

11.5 The Committee after detailed deliberation on the matter recommended that exemption may be granted to M/s Troikaa Pharmaceuticals Ltd. under para 32(i) of DPCO, 2013 with respect to the formulation "Paracetamol Injection (Intramuscular) 250mg/ml" and the recommendation along with written submission of Office of DCGI may be placed before Authority.

Agenda Item No. 12. Report of the Committee to examine the issue relating to 20% reduction of one of the components having lower price while calculating the price of FDCs by the Multidisciplinary Committee of Experts.

12.1 Record note of discussion for private circulation.

Agenda Item No. 13. Retail price fixation under DPCO, 2013- Each ml contains Ibuprofen IP 100mg for M/s Akums Drugs & Pharmaceuticals (manufacturer) and M/s Cipla Ltd. (marketer) (F.No. 3099).

13.1 The matter relates to the retail price fixation of each ml contains Ibuprofen IP 100mg for M/s Akums Drugs & Pharmaceuticals (manufacturer) and M/s Cipla Ltd. (marketer). The matter was deliberated in the 48th meeting of MDC held on 20.01.2023 wherein, committee had noted that data of Ibuprofen 100mg Injection was not available in the Pharmatrac database. The committee had deliberated that Diclofenac and Ibuprofen comes under same Section in NLEM 2022 i.e. "*Section 2 Analgesics, Antipyretics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders.*" Ceiling price of Diclofenac 25mg/ml was already fixed under Scheduled I of DPCO,2013 at Rs.1.63 per ml and the derived retail price of Diclofenac Injection 100 mg/ml Ibuprofen IP 100mg/ml based on formula of Pronab Sen Committee was worked out at Rs.5.05 as below:

The Ceiling Price [SO. 1499(E) dated 30.03.2022] of Diclofenac Injection 25 mg/ml = Rs. 1.63.

Derived retail price of Diclofenac Injection 100 mg/ml as on April, 2022 after applying the formula of Pronab Sen Committee on the price as per (a) above
 $= 1.63[1+0.7\{(100-25)/25\}] = \text{Rs.}5.05$ (excluding GST)

The same was extended to Ibuprofen IP 100mg/ml.

13.2 In above matter, M/s Cipla had Limited filed representation dated 07.02.2023 (copy enclosed) stating that the drug with same dosage & strength is imported and sold by another company at prices almost double (Rs. 30 per ML claimed by M/s Cipla and Rs. 74.375 per ML of other company referred by M/s Cipla) of what applicant has claimed. Applicant had also stated that there are no other manufacturers of the said formulation and notifying retail price suggested by MDC would lead to discouragement of

launching innovative drugs in India. Therefore, applicant requested to fix retail price in line with the market available formulation or as claimed by the company.

13.3 The matter was again deliberated in the 49th meeting of MDC held on 23.02.2023 & 50th meeting of MDC held on 21.04.2023. The committee directed that the applicant i.e. M/s Cipla Limited may be asked to respond particularly on the following:

- (a) Is there any therapeutic advantage of giving Ibuprofen Injection vis-à-vis Diclofenac Injection in terms of efficacy, safety or any other terms?
- (b) If the equivalent dose of Diclofenac Injection and Ibuprofen Injection are used in any therapeutic indication, then what will be the cost of treatment if (i) Diclofenac Injection used; (ii) Ibuprofen Injection used.

13.4 In view of above, letter was sent to M/s Cipla Limited 30.05.2023 seeking the above information. M/s Cipla Limited replied vide letter dated 19.06.2023. The reply of the applicant was placed before the Committee. The applicant was also asked to present their case. However, due to technical issues at the applicant's end, the voice was not audible in the Video Conference.

13.5 Therefore, the Committee deliberated on the matter and decided that the applicant may be asked to present their case in next MDC with specific answer to the queries asked in 50th meeting of MDC held on 21.04.2023.

Agenda Item No. 14. Application for "Special Feature rate" for scheduled products (i) Tazofic Injection 2.25 gm containing Piperacillin 2gm+Tazobactam 250mg and (ii) Tazofic Injection 4.5 gm containing Piperacillin 4gm+Tazobactam 500 mg under Para 11(3) of DPCO 2013.

14.1 The matter related to application filed by M/s Gufic Biosciences Limited on 26.04.2022 for 'Special Feature rate' for scheduled products (i) Tazofic Injection 2.25 gm containing Piperacillin 2gm+Tazobactam 250mg and (ii) Tazofic Injection 4.5 gm containing Piperacillin 4gm+Tazobactam 500 mg under Para 11(3) of DPCO 2013 under 'New Drug Delivery System' namely packing in DCB (Dual Chamber Bags) is as detailed below :

Sl. No	Product Name	Medicines	Dosage form and Strength	Unit	MRP sought
1	Tazofic inj 2.25 gm	Piperacillin (A) + Tazobactam (B)	Powder for Injection 2 g (A) + 250 mg(B)	Each DCB (Dual Chamber Bags) Pack	Rs 665 including GST
2	Tazofic inj 4.5 gm	Piperacillin (A) + Tazobactam (B)	Powder for Injection 4 g (A) + 500 mg(B)	Each DCB (Dual Chamber Bags) Pack	Rs 999 including GST

14.2 The matter was discussed in the various meetings of the Multidisciplinary Committee of Experts. The Committee in its 45th meeting dated 13.09.2022 decided to provide additional 15 % price over the applicable ceiling price of the formulation for incremental innovation of the packaging.

14.3 M/s Gufic Biosciences Ltd. made representation on the recommendation made by the Multidisciplinary Committee of Experts vide letter dated 23.09.2022 stating that dual chamber bags have advantages like prevention of needle stick injuries, assurance of right dosages, avoidance of hospital contamination, DEHP free and hence no risk of cancer, no use of nitrosamines and hence zero risk of cancer etc. The matter was also placed before the Authority in its 102nd meeting held on 27.09.2022 in which the Authority decided that the representation of the company be referred to the Committee for examination.

14.4 Committee, in its 46th meeting held on 20.10.2022 had noted the representation of the company and after deliberation asked the company to submit the additional literature to substantiate their claim and also to make presentation in the next meeting of the committee. In view of this, letter was sent to M/s Gufic Biosciences Ltd on 27.10.2022 requesting to submit the additional literature to substantiate their claim and also to make presentation in the next meeting of the committee. However, no reply was received from the company.

14.5 The matter was again deliberated in 47th meeting of MDC held on 02.12.2022, wherein it was decided that the matter of separate price approval on account special packaging may be taken up after notification of ceiling price of the formulation under Revised Schedule-I of DPCO, 2013 (NLEM 2022).

14.6 The Multidisciplinary Committee of Experts in its 50th meeting held on 21.04.2023 noted that the ceiling price for the FDC of 'Piperacillin +Tazobactam' has been notified by NPPA vide S.O. No. 87(E) dated 06.01.2023 under NLEM, 2022. Further, the committee also noted that applicant i.e. M/s Gufic Biosciences Ltd. has not submitted the additional literature to substantiate their claim as per NPPA's letter dated 27.10.2022. Therefore, after deliberations the committee recommended to reject the application of separate ceiling price of M/s Gufic Biosciences Ltd.

14.7 The above recommendation of the MDC was placed in 113th meeting of Authority held on 26.05.2023, wherein the Authority deliberated on the above matter including the MDC recommendations and decided to refer the matter back to the committee seeking clarification on the recommendation as to :

- a. Whether the request of applicant for price increase over & above 15% has been rejected; thereby recommending 15% additional price over current ceiling price; or
- b. The complete application for separate ceiling price has been recommended for rejection.

14.8 In view of the above, the committee deliberated on the same and clarified that it confirms it's recommendation of additional 15 % price over the present applicable ceiling price of the formulation for incremental innovation for packaging as recommended in the 45th meeting dated 13.09.2022. The committee, however, noted that the present applicable ceiling prices for the said formulations have been refixed under NLEM 2022. Accordingly, the committee recommended the following ceiling prices for M/S Gufic Biosciences Limited under para 11(3) of DPCO 2013 as detailed below:

Sl.	Medicine	Dosage	form	Unit	Ceiling	price	Recommended
-----	----------	--------	------	------	---------	-------	-------------

No.		and strength		(excluding GST) as per SO. 1574(E) dated 31.03.2023	ceiling price under Para 11(3) of DPCO 2013 [(e) X 1.15]
(a)	(b)	(c)	(d)	(e)	(f)
1	Piperacillin (A) + Tazobactam (B)	Powder for Injection 2 g (A) + 250 mg(B)	Each vial	Rs. 191.53	Rs. 220.26 per Dual chamber bag
2	Piperacillin (A) + Tazobactam (B)	Powder for Injection 4 g (A) + 500 mg(B)	Each Vial	Rs. 399.38	Rs. 459.28 per Dual chamber bag

Agenda Item No. 15. Retail price fixation under Para 5 of DPCO, 2013 of new drug that contain molecules or components or ingredients, that have become off-patent or about to become off-patent.

The Committee recollected the deliberations held on new drug that contain molecules or components or ingredients, that have become off-patent or about to become off-patent and the DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 in relation to the same held in it's 51st meeting on 24.05.2023. In line with the said previous deliberations the committee recommended the retail price fixation for the following new drugs that contain molecules or components or ingredients, that have become off-patent or about to become off-patent:

Agenda Item No. 15 (i) Retail price fixation of each uncoated bilayered tablet contains: Vildagliptin (as sustained release) IP 100 mg + Metformin Hydrochloride (as sustained release) IP 1000 mg for M/s Mascot Health Series Pvt. Ltd. (Manufacturer) and M/s Macleods Pharmaceuticals Ltd. (Marketer) under DPCO, 2013 (F.N.3482) at Rs. 13.81 per Tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Mascot Health Series Pvt. Ltd.
2	Marketer Name	M/s Macleods Pharmaceuticals Ltd.
3	Date of Application	22.06.2023
4	Patented Component	Vildagliptin
5	Patent Holder	M/s Novartis Healthcare
6	License Holder	M/s Abbott, M/s Cipla & M/s USV
7	Date of Patent Expiry	9.12.2019

8	Calculation of Retail price	
	Calculated Price excluding PTR (including MAT) of M/s Novartis Healthcare, M/s Abbott, M/s Cipla & M/s USV	
A	Price as on 6 month prior to application date (Nov 22)	10.57
B	Metformin CR 1000 mg (Ceiling Price [SO. 1499(E) dated 30.03.2022]) applicable as on Nov 22	4.05
C	Total	14.62
D	Less: 20% of the lower of (A) and (B)	0.81
E	Worked out Retail Price (C-D)	13.81
F	Claimed Retail price	22.00
	Recommended retail price (Lower of Claimed Price and Worked Out Price) per tablet	13.81

Agenda Item No. 15 (ii) Retail Price fixation of Each uncoated bilayered tablet contains: Vildagliptin (as sustained release) IP 100 mg + Metformin Hydrochloride (as sustained release) IP 500 mg for M/s Mascot Health Series Pvt. Ltd. (Manufacturer) and M/s Macleods Pharmaceuticals Ltd. (Marketer) under DPCO, 2013 (F.No.3483) at Rs. 12.27 per Tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Mascot Health Series Pvt. Ltd.
2	Marketer Name	M/s Macleods Pharmaceuticals Ltd.
3	Date of Application	22.06.2023
4	Patented Component	Vildagliptin
5	Patent Holder	M/s Novartis Healthcare
6	License Holder	M/s Abbott, M/s Cipla & M/s USV
7	Date of Patent Expiry	09.12.2019
8	Calculation of Retail price	
	Calculated Price excluding PTR (including MAT) of M/s Novartis Healthcare, M/s Abbott, M/s Cipla & M/s USV	
A	Price as on 6 month prior to application date (Nov 22)	10.57
B	Metformin CR 500 mg (Ceiling Price [SO. 1499(E) dated 30.03.2022]) applicable as on Nov 22	2.13
C	Total	12.70
D	Less: 20% of the lower of (A) and (B)	0.43
E	Worked out Retail Price (C-D)	12.27
F	Claimed Retail price	18.00

Recommended retail price (Lower of Claimed Price and Worked Out Price) per tablet	12.27
---	-------

Agenda Item No. 15 (iii) Retail Price fixation of Each film coated bilayered tablet contains: Vildagliptin IP 100 mg (as sustained release) + Metformin Hydrochloride IP 1000 mg (as sustained release) for M/s Synokem Pharmaceuticals Ltd.(Manufacturer) and M/s Alkem Laboratories Ltd.(Marketer) under DPCO, 2013 (F.No. 3491)at Rs. 13.81 per Tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Synokem Pharmaceuticals Ltd.
2	Marketer Name	M/s Alkem Laboratories Ltd.
3	Date of Application	23.06.2023
4	Patented Component	Vildagliptin
5	Patent Holder	M/s Novartis Healthcare
6	License Holder	M/s Abbott, M/s Cipla & M/s USV
7	Date of Patent Expiry	9.12.2019
8	Calculation of Retail price	
	Calculated Price excluding PTR (including MAT) of M/s Novartis Healthcare, M/s Abbott, M/s Cipla & M/s USV	
A	Price as on 6 month prior to application date (Nov 22)	10.57
B	Metformin CR 1000 mg (Ceiling Price [SO. 1499(E) dated 30.03.2022]) applicable as on Nov 22	4.05
C	Total	14.62
D	Less: 20% of the lower of (A) and (B)	0.81
E	Worked out Retail Price (C-D)	13.81
F	Claimed Retail price	14.73
	Recommended retail price (Lower of Claimed Price and Worked Out Price) per tablet	13.81

Agenda Item No. 15 (iv) Retail price fixation of Each film coated bilayered tablet contains: Vildagliptin IP 100 mg (as sustained release) + Metformin Hydrochloride IP 500 mg (as sustained release) for M/s Synokem Pharmaceuticals Ltd. (Manufacturer) and M/s Micro Labs Ltd. (Marketer) under DPCO, 2013 (F.No. 3500) at Rs. 12.27 per Tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

A

1	Manufacturer Name	M/s Synokem Pharmaceuticals Ltd.
2	Marketer Name	M/s Micro Labs Limited
3	Date of Application	30.06.2023
4	Patented Component	Vildagliptin
5	Patent Holder	M/s Novartis Healthcare
6	License Holder	M/s Abbott, M/s Cipla & M/s USV
7	Date of Patent Expiry	09.12.2019
8	Calculation of Retail price	
	Calculated Price excluding PTR (including MAT) of M/s Novartis Healthcare, M/s Abbott, M/s Cipla & M/s USV	
A	Price as on 6 month prior to application date (Nov 22)	10.57
B	Metformin CR 500 mg (Ceiling Price [SO. 1499(E) dated 30.03.2022]) applicable as on Nov 22	2.13
C	Total	12.70
D	Less: 20% of the lower of (A) and (B)	0.43
E	Worked out Retail Price (C-D)	12.27
F	Claimed Retail price	12.50
	Recommended retail price (Lower of Claimed Price and Worked Out Price) per tablet	12.27

Agenda Item No. 15 (v) Retail price fixation of each film coated bilayered tablet contains: Vildagliptin IP 100 mg (as sustained release) + Metformin Hydrochloride IP 500 mg (as sustained release) for M/s Synokem Pharmaceuticals Ltd.(Manufacturer) and M/s Alkem Laboratories Ltd.(Marketer) under DPCO, 2013 (F.No.3490) at Rs. 12.27 per Tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Synokem Pharmaceuticals Ltd.
2	Marketer Name	M/s Alkem Laboratories Limited
3	Date of Application	23.06.2023
4	Patented Component	Vildagliptin
5	Patent Holder	M/s Novartis Healthcare
6	License Holder	M/s Abbott, M/s Cipla & M/s USV
7	Date of Patent Expiry	09.12.2019

8	Calculation of Retail price	
	Calculated Price excluding PTR (including MAT) of M/s Novartis Healthcare, M/s Abbott, M/s Cipla& M/s USV	
A	Price as on 6 month prior to application date (Nov 22)	10.57
B	Metformin CR 500 mg (Ceiling Price [SO. 1499(E) dated 30.03.2022]) applicable as on Nov 22	2.13
C	Total	12.70
D	Less: 20% of the lower of (A) and (B)	0.43
E	Worked out Retail Price (C-D)	12.27
F	Claimed Retail price	12.94
	Recommended retail price (Lower of Claimed Price and Worked Out Price) per tablet	12.27

Agenda Item No. 15 (vi) Retail price fixation of Each film coated bilayered tablet contains: Vildagliptin IP 100 mg (as sustained release) + Metformin Hydrochloride IP 1000 mg (as sustained release) for M/s Synokem Pharmaceuticals Ltd. (Manufacturer) and M/s Micro Labs Ltd. (Marketer) under DPCO, 2013 (F.No. 3499) at Rs. 13.81 per Tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Synokem Pharmaceuticals Ltd.
2	Marketer Name	M/s Micro Labs Limited
3	Date of Application	30.06.2023
4	Patented Component	Vildagliptin
5	Patent Holder	M/s Novartis Healthcare
6	License Holder	M/s Abbott, M/s Cipla& M/s USV
7	Date of Patent Expiry	9.12.2019
8	Calculation of Retail price	
	Calculated Price excluding PTR (including MAT) of M/s Novartis Healthcare, M/s Abbott, M/s Cipla& M/s USV	
A	Price as on 6 month prior to application date (Nov 22)	10.57
B	Metformin CR 1000 mg (Ceiling Price [SO. 1499(E) dated 30.03.2022]) applicable as on Nov 22	4.05
C	Total	14.62
D	Less: 20% of the lower of (A) and (B)	0.81
E	Worked out Retail Price (C-D)	13.81
F	Claimed Retail price	13.83

Recommended retail price (Lower of Claimed Price and Worked Out Price) per tablet	13.81
--	--------------

Agenda Item No. 15 (vii): Price fixation of Each uncoated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq to Dapagliflozin 10mg + Vildagliptin 100mg(as sustained released) + Metformin Hydrochloride IP 1000mg(as sustained release)for M/s Mascot Health Series Pvt. Ltd. (Manufacturer) and M/s Macleods Pharmaceuticals Ltd. (Marketer) under DPCO, 2013 (F.No. 3484)at Rs. 20.14 per Tablet excluding GST.

1. The committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Mascot Health Series Pvt. Ltd.
2	Marketer Name	M/s Macleods Pharmaceuticals Ltd.
3	Date of Application	22.06.2023
4	Patented Component I	Dapagliflozin
5	Patent Holder	M/s Astra Zeneca
6	License Holder	M/s Sun Pharma and M/s Abbott Healthcare
7	Date of Patent Expiry	02.10.2020
8	Patented Component II	Vildagliptin
9	Patent Holder	M/s Novartis Healthcare
10	License Holder	M/s Abbott, M/s Cipla& M/s USV
11	Date of Patent Expiry	9.12.2019


Calculation of Retail Price

S.N.	Particulars	Data Month	(Option I) Vildagliptin (100mg) + Metformin (1000mg)	(Option II) Dapagliflozin (10mg) + Metformin (1000mg)
A.	Retail price of FDC excluding Patent & License Holder	Nov 22	NA	11.68
B.	Other Component excluding Patent & License Holder	Nov 22	11.66 (Dapagliflozin 10mg)	10.57 (Vildagliptin 100mg)
C.	Total		NA	22.25
D.	Less: 20% of lower of A&B		NA	2.11
E.	Calculated Price of applied FDC		NA	20.14
F.	Claimed Price		NA	25.00
	Recommended retail price (Lower of Claimed Price and Option I, Option II)			20.14

Agenda Item No. 16: Retail price fixation under DPCO, 2013- Each 5ml contains: Ambroxol Hydrochloride IP 15 mg + Salbutamol Sulphate IP eq. to Salbutamol 1 mg + Guaiphenesin IP 50 mg + Menthol IP 1 mg for M/s Naxpar Pharma Pvt. Ltd. (manufacturer) and M/s Geno Pharmaceuticals Pvt. Ltd.(marketer) (F.No. 3323).

16.1 Due to paucity of time, the agenda could not be deliberated. Hence, the same was deferred for the next MDC.

The meeting ended with a vote of thanks to all.



(Mahaveer Saini)
Deputy Director (Pricing)

Copy to:
All members of the Committee.

Computation of Retail Price based on oct, 2022 Data under Para 5 of DPCO, 2013

Each uncoated bilayered tablet contains: Azelnidipine IP 16 mg	Number of Companies consisting of Market Share of 1% & Above	7
	Sum of MAT value considered for price calculation (in Lakhs)	1,470.82
	Sum of PTR per unit considered for price calculation	73.00
	Number of Packs considered	7
	Average PTR	10.43
	Add: 16% Retailer Margin	1.67
	Retail Price (without local taxes)	12.10
% Reduction with compared to Highest Price	13.08%	

Minimum Price (Rs.)	9.29
Maximum Price (Rs.)	12.00
Average of all considered (Rs.)	10.43
Retail Price (Rs.)	12.1

S.No.	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR	14,76,19,354	100%	Brandwise MAT (ignoring 0% MAT)	Qualify (Y/N) Y=Yes N=No	M3	Price per unit (Rs.) Considered
								MAT(Rs.)	SKU wise MAT %			Price per unit (Rs.)	
1	AZELDIP 16 MG TABLET 10	AZELDIP	GLENMARK PHARMACEUTICALS LTD.	16 MG	10	TABLET	109.29	2562944	1.74%	1.74%	Y	10.93	10.93
2	AZELIREN 16 MG TABLET 10	AZELIREN	LA RENON	16 MG	10	TABLET	110.00	2138880	1.45%	1.45%	Y	11.00	11.00
3	AZILTA 16 MG TABLET 10	AZILTA	RPG LIFE SCIENCES LTD.	16 MG	10	TABLET	100.00	453000	0.31%	0.31%	N	10.00	
4	AZOVAS 16 MG TABLET 10	AZOVAS	JB CHEMICALS	16 MG	10	TABLET	94.25	11107640	7.52%	7.52%	Y	9.43	9.43
5	AZUSA 16 MG TABLET 10	AZUSA	AJANTA PHARMA LTD	16 MG	10	TABLET	102.14	25502049	17.28%	17.28%	Y	10.21	10.21
6	CORAZEL 16 MG TABLET 10	CORAZEL	FUSION HEALTHCARE PVT LTD	16 MG	10	TABLET	99.29	84794	0.06%	0.06%	N	9.93	
7	EMDIP 16 MG TABLET 10	EMDIP	EMCURE PHARMACEUTICALS LTD	16 MG	10	TABLET	92.86	4377699	2.97%	2.97%	Y	9.29	9.29
8	UNIAZ 16 MG TABLET 10	UNIAZ	TORRENT PHARMACEUTICALS LTD.	16 MG	10	TABLET	120.04	67016306	45.40%	45.40%	Y	12.00	12.00
9	ZEBLONG 16 MG TABLET 10	ZEBLONG	IPCA LABORATORIES PVT LTD.	16 MG	10	TABLET	101.42	34376043	23.29%	23.29%	Y	10.14	10.14
			Rs. Per Tablet										
	Worked out Retail Price	12.10	Excluding GST										

Computation of Retail Price based on October, 2022 Data under Para 5 of DPCO, 2013

Each uncoated bilayered tablet contains: Bisoprolol Fumarate IP 2.5 mg	Number of Companies consisting of Market Share of 1% & Above				7
	Sum of MAT value considered for price calculation (in Lakhs)				10,284.56
	Sum of PTR per unit considered for price calculation				31.78
	Number of Packs considered				8
	Average PTR				3.97
	Add: 16% Retailer Margin				0.64
	Retail Price (without local taxes)				4.61
% Reduction with compared to Highest Price					21.70%

Minimum Price (Rs.)			2.43
Maximum Price (Rs.)			5.07
Average of all considered (Rs.)			3.97
Retail Price (Rs.)			4.61

S.No.	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR	1,03,82,51,876	100%	M3			Price per unit (Rs.) Considered
								MAT(Rs.)	SKU wise MAT %	Brandwise MAT (ignoring 0% MAT)	Qualify (Y/N) Y=Yes N=No	Price per unit (Rs.)	
1	BESICOR 2.5 MG TABLET 10	BESICOR	AJANTA PHARMA LTD	2.5 MG	10	TABLET	32.43	20066419	1.93%	2.04%	Y	3.24	3.24
2	BESICOR 2.5 MG TABLET 15	BESICOR	AJANTA PHARMA LTD	2.5 MG	15	TABLET	57.50	1178750	0.11%	2.04%	Y	3.83	3.83
3	BESOLOC 2.5 MG TABLET 10	BESOLOC	EAST WEST PHARMA	2.5 MG	10	TABLET	31.86	20900	0.00%	0.00%	N	3.19	
4	BIBETA 2.5 MG TABLET 10	BIBETA	OPSCARE LIFESCIENCE PVT LTD	2.5 MG	10	TABLET	35.71	290037	0.03%	0.03%	N	3.57	
5	BISELECT 2.5 MG TABLET 10	BISELECT	INTAS PHARMACEUTICALS LTD	2.5 MG	10	TABLET	24.29	11175137	1.08%	1.08%	Y	2.43	2.43
6	BISOACE 2.5 MG TABLET 10	BISOACE	MOREPEN LABORATORIES LIMITED	2.5 MG	10	TABLET	6.00	15540	0.00%	0.00%	N	0.60	
7	BISOBIS 2.5 MG TABLET 10	BISOBIS	CORONA	2.5 MG	10	TABLET	28.57	2612755	0.25%	0.25%	N	2.86	
8	BISOCAR 2.5 MG TABLET 10	BISOCAR	RUSAN HEALTHCARE PVT. LTD	2.5 MG	10	TABLET	18.57	4663	0.00%	0.00%	N	1.86	
9	BISODER 2.5 MG TABLET 10	BISODER	ELDER PHARMACEUTICALS LTD	2.5 MG	10	TABLET	35.71	107	0.00%	0.00%	N	3.57	
10	BISOHEART 2.5 MG TABLET 10	BISOHEART	MANKIND PHARMACEUTICALS LTD.	2.5 MG	10	TABLET	36.14	64037080	6.17%	6.17%	Y	3.61	3.61
11	BISOLONG 2.5 MG TABLET 10	BISOLONG	MICRO LABS LTD	2.5 MG	10	TABLET	35.00	1650085	0.16%	0.16%	N	3.50	
12	BISONEXT 2.5 MG TABLET 15	BISONEXT	LUPIN LTD	2.5 MG	15	TABLET	68.86	38209014	3.68%	3.68%	Y	4.59	4.59
13	BISOSAFE 2.5 MG TABLET 10	BISOSAFE	ABBOTT HEALTHCARE PVT. LTD	2.5 MG	10	TABLET	39.29	3743473	0.36%	0.36%	N	3.93	
14	BISOTAB 2.5 MG TABLET 10	BISOTAB	JB CHEMICALS	2.5 MG	10	TABLET	49.84	18377469	1.77%	1.77%	Y	4.98	4.98
15	BISVEDA 2.5 MG TABLET 10	BISVEDA	KEPLER HEALTH CARE	2.5 MG	10	TABLET	34.57	1287421	0.12%	0.12%	N	3.46	
16	BIZO 2.5 MG TABLET 10	BIZO	SPECTRA THERAPEUTICS PVT. LTD.	2.5 MG	10	TABLET	30.00	160200	0.02%	0.02%	N	3.00	
17	CONCOR COR 2.5 MG TABLET 10	CONCOR COR	MERCK SPECIALITIES PVT.LTD	2.5 MG	10	TABLET	50.71	752328083.3	72.46%	72.46%	Y	5.07	5.07
18	CONCOVAS 2.5 MG TABLET 10	CONCOVAS	VASU ORGANICS PVT.LTD	2.5 MG	10	TABLET	47.57	10541.39	0.00%	0.00%	N	4.76	
19	CORBIS 2.5 MG TABLET 15	CORBIS	TORRENT PHARMACEUTICALS LTD.	2.5 MG	15	TABLET	60.39	123084200.5	11.85%	11.85%	Y	4.03	4.03
		Rs. Per Tablet											
	Worked out Retail Price	4.61	Excluding GST										

Computation of Retail Price based on October, 2022 Data under Para 5 of DPCO, 2013

Each uncoated bilayered tablet contains: Bisoprolol Fumarate IP 5 mg	Number of Companies consisting of Market Share of 1% & Above	5
	Sum of MAT value considered for price calculation (in Lakhs)	12,709.00
	Sum of PTR per unit considered for price calculation	31.24
	Number of Packs considered	5
	Average PTR	6.25
	Add : 16% Retailer Margin	1.00
	Retail Price (without local taxes)	7.25
	% Reduction with compared to Highest Price	17.44%

Minimum Price (Rs.)	--	4.40
Maximum Price (Rs.)		7.57
Average of all considered (Rs.)		6.25
Retail Price (Rs.)		7.25

S.No.	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR	#####	100%	M3			Price per unit (Rs.)	Price per unit (Rs.) Considered
								MAT (Rs.)	SKU wise MAT %	Brandwise MAT (ignoring 0% MAT)	Qualify (Y/N) Y=Yes N=No	Price per unit (Rs.)		
1	ACBISO 5 MG TABLET 10	ACBISO	ACMEDIX PHARMA LLP	5 MG	10	TABLET	20.71	270017	0.02%	0.02%	N	2.07		
2	BESICOR 5 MG TABLET 10	BESICOR	AJANTA PHARMA LTD	5 MG	10	TABLET	48.21	3605626	0.28%	0.40%	N	4.82		
3	BESICOR 5 MG TABLET 15	BESICOR	AJANTA PHARMA LTD	5 MG	15	TABLET	85.71	1510800	0.12%	0.40%	N	5.71		
4	BESIDOC 5 MG TABLET 10	BESIDOC	EAST WEST PHARMA	5 MG	10	TABLET	26.43	1031	0.00%	0.00%	N	2.64		
5	BIBETA 5 MG TABLET 10	BIBETA	OPISICARE LIFESCIENCE PVT LTD	5 MG	10	TABLET	42.86	309878	0.02%	0.02%	N	4.29		
6	BISELECT 5 MG TABLET 10	BISELECT	INTAS PHARMACEUTICALS LTD	5 MG	10	TABLET	30.36	12907540	0.99%	0.99%	N	3.04		
7	BISOACE 5 MG TABLET 10	BISOACE	MOREPEN LABORATORIES LIMITED	5 MG	10	TABLET	8.77	21355	0.00%	0.00%	N	0.88		
8	BISOBIS 5 MG TABLET 10	BISOBIS	CORONA	5 MG	10	TABLET	28.57	3185984	0.24%	0.24%	N	2.86		
9	BISOCAR 5 MG TABLET 10	BISOCAR	RUSAN HEALTHCARE PVT. LTD	5 MG	10	TABLET	27.14	4532	0.00%	0.00%	N	2.71		
10	BISOHEART 5 MG TABLET 10	BISOHEART	MANKIND PHARMACEUTICALS LTD.	5 MG	10	TABLET	56.89	96470478	7.36%	7.36%	Y	5.69	5.69	
11	BISOLONG 5 MG TABLET 10	BISOLONG	MICRO LABS LTD	5 MG	10	TABLET	50.71	3851025	0.29%	0.29%	N	5.07		
12	BISONEXT 5 MG TABLET 15	BISONEXT	LUPIN LTD	5 MG	15	TABLET	93.29	48280116	3.69%	3.69%	Y	6.22	6.22	
13	BISOSAFE 5 MG TABLET 10	BISOSAFE	ABBOTT HEALTHCARE PVT. LTD	5 MG	10	TABLET	60.49	7283002	0.56%	0.56%	N	6.05		
14	BISOTAB 5 MG TABLET 10	BISOTAB	JB CHEMICALS	5 MG	10	TABLET	73.58	23796369	1.82%	1.82%	Y	7.36	7.36	
15	BISVEDA 5 MG TABLET 10	BISVEDA	KEPLER HEALTH CARE	5 MG	10	TABLET	47.54	2784418	0.21%	0.21%	N	4.75		
16	BIZO 5 MG TABLET 10	BIZO	SPECTRA THERAPEUTICS PVT. LTD.	5 MG	10	TABLET	35.72	281152	0.02%	0.02%	N	3.57		
17	CONCOR 5 MG TABLET 10	CONCOR	MERCK SPECIALITIES PVT.LTD	5 MG	10	TABLET	75.68	951691377	72.64%	72.64%	Y	7.57	7.57	
18	CONCOVAS 5 MG TABLET 10	CONCOVAS	VASU ORGANICS PVT.LTD	5 MG	10	TABLET	56.57	88532.05	0.01%	0.01%	N	5.66		
19	CORRIS 5 MG TABLET 15	CORRIS	TORRENT PHARMACEUTICALS LTD.	5 MG	15	TABLET	66.07	150661865.6	11.50%	11.50%	Y	4.40	4.40	
20	ZABESTA 5 MG TABLET 10	ZABESTA	USV PVT LTD	5 MG	10	TABLET	49.43	3124470.3	0.24%	0.24%	N	4.94		
		Rs. Per Tablet												
	Worked out Retail Price	7.25	Excluding GST											

Computation of Retail Price based on November, 2022 Data under Para 5 of DPCO, 2013													
Vildagliptin 100mg													
Number of Companies consisting of Market Share of 1% & Above													
Sum of MAT value considered for price calculation (In Lakhs)													
Sum of PTR per unit considered for price calculation													
Number of Packs considered													
Average PTR													
Add: 16% Retailer Margin													
Retail Price (without local taxes)													
% Reduction with compared to Highest Price													
Minimum Price (Rs.)													
Maximum Price (Rs.)													
Average of all considered (Rs.)													
Retail Price (Rs.)													
S.No.	पैक विवरण Pack Description	ब्रांड BRAND	कंपनी Company	Strength	Pack Size	Unit	TOTAL MAT PTR(Rs.)	70,86,02,362 MAT(Rs.)	100% SKU wise MAT %	Brandwise MAT (ignoring 0% MAT)	Qualify (Y/N Yes N=No	M3 Price per Unit (Rs.)	Price per Unit (Rs.) Considered
1	ABVIDA 100 MG TABLET SR 15	ABVIDA	ABBOTT HEALTHCARE PVT. LTD.	100 MG	15	TABLET SR	153.2						
2	VILATIN 100 MG TABLET SR 15	VILATIN	AJANTA PHARMA LTD	100 MG	15	TABLET SR	129.93	15432811.85	2.18%	2.18%	Y	8.80	8.60
3	VILDANA 100 MG TABLET SR 10	VILDANA	AXESS PHARMA (P) LTD	100 MG	10	TABLET SR	92.86	5960690.02	0.84%	0.84%	N	9.29	
4	GLUPY OD 100 MG TABLET SR 15	GLUPY	ALEMBOIC LTD	100 MG	15	TABLET SR	128.57	24027675.88	3.38%	3.38%	Y	8.57	8.57
5	VILDAMBIC OD 100 MG TABLET SR 10	VILDAMBIC	ALEMBOIC LTD	100 MG	10	TABLET SR	70.71	1717404.48	0.24%	0.24%	N	7.07	
6	GLUVILDA OD 100 MG TABLET SR 15	GLUVILDA	ALIKEM LABORATORIES LTD.	100 MG	15	TABLET SR	117.86	54052482.66	7.63%	7.63%	Y	7.86	7.86
7	VILTAB 100 MG TABLET SR 15	VILTAB	ALTEUS BIOGENICS PVT.LTD.	100 MG	15	TABLET SR	106.07	138164.76	0.02%	0.02%	N	7.07	
8	VILDAGARD OD 100 MG TABLET SR 15	VILDAGARD OD	ARISTO PHARMACEUTICALS PVT.LTD	100 MG	15	TABLET SR	96.43	448303.07	0.06%	0.06%	N	6.43	
9	BIOVILDA 100 MG TABLET SR 10	BIOVILDA	BIOS LAB PVT LTD	100 MG	10	TABLET SR	90	784550.00	0.11%	0.11%	N	9.00	
10	VILAPIL SR 100 MG TABLET SR 10	VILAPIL SR	CADELL HEALTH CARE PVT.LTD	100 MG	10	TABLET SR	67.86	648538.02	0.09%	0.09%	N	6.78	
11	GAIVUS 100 MG TABLET 15	GAIVUS	CIPLA LTD.	100 MG	15	TABLET	407.15						
12	VISOV 100 MG TABLET XR 15	VISOV	CIPLA LTD.	100 MG	15	TABLET XR	152.04						
13	VIBITE 100 MG TABLET SR 15	VIBITE	CORDONA	100 MG	15	TABLET SR	116.68	12456482.76	1.76%	1.76%	Y	7.78	7.78
14	VSMALL OD 100 MG TABLET SR 10	VSMALL	DR. REDDYS LABORATORIES LTD	100 MG	10	TABLET SR	71.43	4754952.24	0.67%	0.67%	N	7.14	
15	VVIDA OD 100 MG TABLET SR 15	VVIDA	EMCURE PHARMACEUTICALS LTD	100 MG	15	TABLET SR	175.43	106298529.48	15.00%	15.00%	Y	11.70	11.70
16	ZOMELIS 100 MG TABLET SR 10	ZOMELIS	ERIS LIFESCIENCES LTD	100 MG	10	TABLET SR	85.64	42957550.75	6.06%	7.90%	Y	8.56	8.56
17	ZOMELIS 100 MG TABLET SR 15	ZOMELIS	ERIS LIFESCIENCES LTD	100 MG	15	TABLET SR	128.46	13061941.26	1.84%	7.90%	Y	8.56	8.56
18	VINSORIN OD 100 MG TABLET SR 10	VINSORIN	FUSION HEALTHCARE PVT LTD	100 MG	10	TABLET SR	89.29	676103.88	0.10%	0.10%	N	8.93	
19	GLUPACURE OD 100 MG TABLET SR 15	GLUPACURE	HBC LIFESCIENCES PVT LTD	100 MG	15	TABLET SR	117.86	634086.80	0.09%	0.09%	N	7.86	
20	IBVILDA OD 100 MG TABLET SR 10	IBVILDA	INDIABULLS PHARMACEUTICALS LTD	100 MG	10	TABLET SR	89.29	642620.13	0.09%	0.09%	N	8.93	
21	INTAGLIP OD 100 MG TABLET SR 10	INTAGLIP	INTAS PHARMACEUTICALS LTD	100 MG	10	TABLET SR	117.14	32881155.08	4.64%	4.64%	Y	11.71	11.71
22	ZAVA OD 100 MG TABLET SR 10	ZAVA	INTAS PHARMACEUTICALS LTD	100 MG	10	TABLET SR	117.14	68075603.76	9.61%	9.61%	Y	11.71	11.71
23	JUBIVILDA 100 MG TABLET SR 15	JUBIVILDA	JUBILANT GENERICS LIMITED	100 MG	15	TABLET SR	107.14	5048663.64	0.57%	0.57%	N	7.14	
24	VILDANEX SR 100 MG TABLET SR 10	VILDANEX SR	LLOYD HEALTHCARE PVT.LTD	100 MG	10	TABLET SR	78.58	6422893.46	0.91%	0.91%	N	7.86	
25	VILDARAY SR 100 MG TABLET SR 10	VILDARAY SR	LLOYD HEALTHCARE PVT.LTD	100 MG	10	TABLET SR	78.58	17799705.86	2.51%	2.51%	Y	7.86	7.86
26	VERIFICA 100 MG TABLET SR 10	VERIFICA	LUPIN LTD	100 MG	10	TABLET SR	114.29	29636882.72	4.18%	4.18%	Y	11.43	11.43
27	VILDAMAC OD 100 MG TABLET SR 15	VILDAMAC	MACLEODS PHARMACEUTICALS PVT.LTD	100 MG	15	TABLET SR	141.43	33798630.12	4.78%	4.78%	Y	9.43	9.43
28	GLUPTAGREAT OD 100 MG TABLET SR 10	GLUPTAGREAT	MANKIND PHARMACEUTICALS LTD.	100 MG	10	TABLET SR	77.79	48103895.97	6.79%	6.79%	Y	7.78	7.78
29	VILACT 100 MG TABLET XR 10	VILACT	MANKIND PHARMACEUTICALS LTD.	100 MG	10	TABLET XR	107.14	1369463.48	0.19%	0.19%	N	10.71	
30	ZUKANORM 100 MG TABLET SR 10	ZUKANORM	MANKIND PHARMACEUTICALS LTD.	100 MG	10	TABLET SR	70.71	23262105.09	3.28%	3.28%	Y	7.07	7.07
31	VILDARLIS 100 MG TABLET SR 10	VILDARLIS	MED MANOR ORGANICS PVT LTD.	100 MG	10	TABLET SR	85.71	24065.45	0.00%	0.00%	N	8.57	
32	VIDAGLO OD 100 MG TABLET SR 10	VIDAGLO	MEDLEY PHARMACEUTICALS	100 MG	10	TABLET SR	92.86	5234796.78	0.74%	0.74%	N	9.29	
33	VILDAPRIDE OD 100 MG TABLET SR 10	VILDAPRIDE	MICRO LABS LTD	100 MG	10	TABLET SR	93.57	31013468.49	4.38%	4.38%	Y	9.36	9.36
34	VILPOWER OD 100 MG TABLET SR 15	VILPOWER	MICRO LABS LTD	100 MG	15	TABLET SR	140	14738203.38	2.08%	2.08%	Y	9.33	9.33

35	VILMUR OD 100 MG TABLET SR 15	VILMUR	OPISICARE LIFESCIENCE PVT LTD	100 MG	15	TABLET SR	106.07	532577.47	0.08%	0.08%	N	7.07	
36	VILDAPRIME 100 MG TABLET SR 15	VILDAPRIME	PRIMUS REMEDIES PVT LTD	100 MG	15	TABLET SR	117.86	2918685.04	0.41%	0.41%	N	7.86	
37	VILSURE 100 MG TABLET SR 15	VILSURE	SINISAN PHARMACEUTICALS	100 MG	15	TABLET SR	160.71	492254.73	0.07%	0.07%	N	10.71	
38	VILDASPEC 100 MG TABLET SR 10	VILDASPEC	SPECTRA.THERAPEUTICS PVT. LTD.	100 MG	10	TABLET SR	74.65	1073433.41	0.15%	0.15%	N	7.47	
39	ENCELIN OD 100 MG TABLET SR 10	ENCELIN	TORRENT PHARMACEUTICALS LTD.	100 MG	10	TABLET SR	86.43	45685037.01	6.45%	6.45%	Y	8.64	8.64
40	TORGLIP OD 100 MG TABLET SR 10	TORGLIP	TORRENT PHARMACEUTICALS LTD.	100 MG	10	TABLET SR	86.32	30328917.27	4.28%	4.28%	Y	8.63	8.63
41	VILASON OD 100 MG TABLET SR 10	VILASON	UNISON PHARMACEUTICALS	100 MG	10	TABLET SR	42.86	1967874.04	0.28%	0.28%	N	4.29	
42	JALRA OD 100 MG TABLET SR 10	JALRA	USV PVT LTD	100 MG	10	TABLET SR	128.57						
43	O VILDALOG 100 MG TABLET SR 10	O VILDALOG	WOCKHARDT LTD	100 MG	10	TABLET SR	142.86	4013080.26	0.57%	0.57%	N	14.29	
44	VINGLYN 100 MG TABLET SR 10	VINGLYN	ZYDUS CADILA - ZHL	100 MG	10	TABLET SR	85.04	20574783.00	2.90%	2.90%	Y	8.60	8.60
		Rs. Per Capsule											
	Worked out Retail Price	10.57	Excluding GST										

36	DAPABUS M 10/1000 MG TABLET 10	DAPABUS M	MED MANOR ORGANICS PVT LTD.	10/1000 MG	10	TABLET	97.86	75645.78	0.02%	0.02%	N	8.79	
37	DAPANOVA M 10/1000 MG TABLET 15	DAPANOVA M	MEDLEY PHARMACEUTICALS	10/1000 MG	15	TABLET	182.14	19142003.30	4.23%	4.23%	Y	12.14	12.14
38	DAJIO M 10/1000 MG TABLET 10	DAJIO M	MICRO LABS LTD	10/1000 MG	10	TABLET	103.71	10611275.51	2.34%	2.34%	Y	10.57	10.57
39	ZUCAPRIDE M 10/1000 MG TABLET 10	ZUCAPRIDE M	MICRO LABS LTD	10/1000 MG	10	TABLET	115.71	59406465.89	13.12%	13.12%	Y	11.07	11.07
40	DAPACNE M 10/1000 MG TABLET 10	DAPACNE M	VSN LABORATORIES LTD	10/1000 MG	10	TABLET	86.43	450690.22	0.98%	0.98%	N	9.64	
41	DAPABEST M 10/1000 MG TABLET 10	DAPABEST M	PANACEA BIOTEC LTD	10/1000 MG	10	TABLET	80.56	250880.48	0.66%	0.66%	N	8.86	
42	GLUFOPRIME M 10/1000 MG TABLET 15	GLUFOPRIME M	PRIMUS REMEDIES PVT LTD	10/1000 MG	15	TABLET	134.04	611088.36	0.13%	0.13%	N	8.94	
43	DPO M 10/1000 MG TABLET 10	DPO M	RPG LIFE SCIENCES LTD.	10/1000 MG	10	TABLET	109.57	855488.20	0.19%	0.19%	N	10.39	
44	MDAPA 10 M FORTE 10/1000 MG TABLET 10	MDAPA 10 M FORTE	SINSAN PHARMACEUTICALS	10/1000 MG	10	TABLET	193.99	373396.84	0.08%	0.08%	N	13.39	
46	MDAPA 10 M FORTE 10/1000 MG TABLET 15	MDAPA 10 M FORTE	SINSAN PHARMACEUTICALS	10/1000 MG	15	TABLET	79.5	9377.13	0.00%	0.00%	N	5.30	
46	SINXIGA 10 M FORTE 10/1000 MG TABLET 15	SINXIGA 10 M FORTE	SINSAN PHARMACEUTICALS	10/1000 MG	15	TABLET	133.99	53839.86	0.01%	0.01%	N	8.93	
47	SINXIGA M FORTE 10/1000 MG TABLET 10	SINXIGA M	SINSAN PHARMACEUTICALS	10/1000 MG	10	TABLET	133.99	251252.68	0.09%	0.09%	N	13.39	
48	OKRAMET M 10/1000 MG TABLET XR 7	OKRAMET M	SUN PHARMA LABORATORIES LTD.	10/1000 MG	7	TABLET XR	79.5						
48	OKRAMET 10/1000 MG TABLET XR 7	OKRAMET	SUN PHARMA LABORATORIES LTD.	10/1000 MG	7	TABLET XR	79.5						
60	GLUCRETA M 10/1000 MG TABLET 10	GLUCRETA M	TORRENT PHARMACEUTICALS LTD.	10/1000 MG	10	TABLET	107.72	5629922.62	12.43%	12.43%	Y	10.78	10.78
60	GLUCRETA M 10/1000 MG TABLET 10	GLUCRETA M	TORRENT PHARMACEUTICALS LTD.	10/1000 MG	10	TABLET	53.57	637054.44	0.14%	0.14%	N	5.36	
51	DGSSON M 10/1000 MG TABLET 10	DGSSON M	UNISON PHARMACEUTICALS	10/1000 MG	10	TABLET	109.9	41302445.70	9.12%	9.12%	Y	10.39	10.39
52	UDAPA M 10/1000 MG TABLET XR 10	UDAPA M	USV PVT LTD	10/1000 MG	10	TABLET XR	138.36	2057551.56	0.45%	0.45%	N	9.22	
53	DIUTEN M 10/1000 MG TABLET 15	DIUTEN M	WOCKHARDT LTD	10/1000 MG	15	TABLET	138.36	4254765.84	0.94%	0.94%	N	9.22	
54	ZINODAP M 10/1000 MG TABLET SR 15	ZINODAP M	WOCKHARDT LTD	10/1000 MG	15	TABLET SR	138.36	2057551.56	0.45%	0.45%	N	9.22	
55	DAPAFORMIN 10/1000 MG TABLET 10	DAPAFORMIN	ZUVENTUS HEALTHCARE LTD	10/1000 MG	10	TABLET	96.43	602880.36	0.13%	0.13%	N	9.64	
56	DAPAGLYN M 10/1000 MG TABLET 15	DAPAGLYN M	ZYDUS CADILA - ZHL	10/1000 MG	15	TABLET	141.71	23734582.77	5.24%	5.24%	Y	9.45	9.45
		Rs. Per Tablet											
		11.68	Excluding GST										
	Worked out Retail Price												

114

Computation of Retail Price based on November, 2022 Data under Para 5 of OPCO, 2013

Vildagliptin (as sustained release) - P 100 mg	Number of Companies consisting of Market Share of 1% & Above	14
	Sum of MAT value considered for price calculation (in Lacs)	6,641.26
	Sum of PTR per unit considered for price calculation	173.18
	Number of Packs considered	19
	Average PTR	9.11
	Add : 16% Retailer Margin	1.46
	Retail Price (without local taxes)	10.57
	% Reduction with compared to Highest Price	22.20%

Minimum Price (Rs.)	7.07
Maximum Price (Rs.)	11.71
Average of all considered (Rs.)	9.33
Retail Price (Rs.)	10.57

S.No.	पैक विवरण Pack Description	उत्प BRAND	कंपनी Company	Strength	Pack Size	Unit	TOTAL MAT	70,86,02,362	100%	Brandwise e MAT (Ignoring 0% MAT)	Qualify (Y/N) Y=Yes N=No	Price per Unit (Rs.)	Price per Unit (Rs.) Considered
							PTR(Rs.)	MAT(Rs.)	SKU wise MAT %				
1	ABVIDA 100 MG TABLET SR 15	ABVIDA	ABBOTT HEALTHCARE PVT. LTD	100 MG	15	TABLET SR	159.2						
2	VILATIN 100 MG TABLET SR 15	VILATIN	AJANTA PHARMA LTD	100 MG	15	TABLET SR	128.03	15432811.85	2.18%	2.18%	Y	8.60	8.60
3	VILDANA 100 MG TABLET SR 10	VILDANA	AKESISS PHARMA (P) LTD	100 MG	10	TABLET SR	91.86	5960690.02	0.84%	0.84%	N	9.29	
4	GLUPY OD 100 MG TABLET SR 15	GLUPY	ALEMBIC LTD	100 MG	15	TABLET SR	128.57	24027675.88	3.39%	3.39%	Y	8.57	8.57
5	VILDAMBIC OD 100 MG TABLET SR 10	VILDAMBIC	ALEMBIC LTD	100 MG	10	TABLET SR	70.71	1717404.48	0.24%	0.24%	N	7.07	
6	GLUVILDA 100 MG TABLET SR 15	GLUVILDA	ALKEM LABORATORIES LTD.	100 MG	15	TABLET SR	117.86	54052482.66	7.53%	7.53%	Y	7.88	7.88
7	VILTAB 100 MG TABLET SR 15	VILTAB	ALTEUS BIOGENICS PVT.LTD.	100 MG	15	TABLET SR	106.07	138164.76	0.02%	0.02%	N	7.07	
8	VILDAGARD OD 100 MG TABLET SR 15	VILDAGARD OD	ARISTO PHARMACEUTICALS PVT.LTD	100 MG	15	TABLET SR	96.43	4489309.07	0.06%	0.06%	N	8.43	
9	BIOVILDA 100 MG TABLET SR 10	BIOVILDA	BIOS LAB PVT LTD	100 MG	10	TABLET SR	9C	764550.00	0.11%	0.11%	N	9.00	
10	VILAPIL SR 100 MG TABLET SR 10	VILAPIL SR	CADELL HEALTH CARE PVT.LTD	100 MG	10	TABLET SR	67.86	648538.02	0.09%	0.09%	N	8.78	
11	GALVUS 100 MG TABLET SR 15	GALVUS	CIPLA LTD.	100 MG	15	TABLET SR	407.15						
12	VYSOV 100 MG TABLET SR 15	VYSOV	CIPLA LTD.	100 MG	15	TABLET SR	152.04						
13	VIBITE 100 MG TABLET SR 15	VIBITE	CORONA	100 MG	15	TABLET SR	116.68	12456482.78	1.76%	1.76%	Y	7.78	7.78
14	VSMALL OD 100 MG TABLET SR 10	VSMALL	DR. REDDYS LABORATORIES LTD	100 MG	10	TABLET SR	71.43	4754952.24	0.67%	0.67%	N	7.14	
15	VYLDA OD 100 MG TABLET SR 15	VYLDA	EMCURE PHARMACEUTICALS LTD	100 MG	15	TABLET SR	175.43	106298529.48	15.00%	15.00%	Y	11.70	11.70
16	ZOMELIS 100 MG TABLET SR 10	ZOMELIS	ERIS LIFESCIENCES LTD	100 MG	10	TABLET SR	85.64	43957590.75	6.06%	7.90%	Y	8.56	8.56
17	ZOMELIS 100 MG TABLET SR 15	ZOMELIS	ERIS LIFESCIENCES LTD	100 MG	15	TABLET SR	128.46	13061941.26	1.94%	7.90%	Y	8.56	8.56
18	VINSORIN OD 100 MG TABLET SR 10	VINSORIN	FUSION HEALTHCARE PVT LTD	100 MG	10	TABLET SR	89.29	676103.88	0.10%	0.10%	N	8.93	
19	GLUPACURE OD 100 MG TABLET SR 15	GLUPACURE	HBC LIFESCIENCES PVT LTD	100 MG	15	TABLET SR	117.86	694086.80	0.09%	0.09%	N	7.88	
20	IBVILDA OD 100 MG TABLET SR 10	IBVILDA	INDIABULLS PHARMACEUTICALS LTD	100 MG	10	TABLET SR	89.29	842620.13	0.09%	0.09%	N	8.93	
21	INTAGLIP OD 100 MG TABLET SR 10	INTAGLIP	INTAS PHARMACEUTICALS LTD	100 MG	10	TABLET SR	117.14	32881155.08	4.64%	4.64%	Y	11.71	11.71
22	ZAVA OD 100 MG TABLET SR 10	ZAVA	INTAS PHARMACEUTICALS LTD	100 MG	10	TABLET SR	117.14	68075603.76	6.61%	9.81%	Y	11.71	11.71
23	JUBVILDA 100 MG TABLET SR 15	JUBVILDA	JUBILANT GENERICS LIMITED	100 MG	15	TABLET SR	107.14	4041963.64	0.57%	0.57%	N	7.14	
24	VILDANEX SR 100 MG TABLET SR 10	VILDANEX SR	LLOYD HEALTHCARE PVT.LTD	100 MG	10	TABLET SR	78.58	6422893.46	0.91%	0.91%	N	7.86	
25	VILDARAY SR 100 MG TABLET SR 10	VILDARAY SR	LLOYD HEALTHCARE PVT.LTD	100 MG	10	TABLET SR	78.58	17799705.86	2.51%	2.51%	Y	7.86	7.86
26	VERIFICA 100 MG TABLET SR 10	VERIFICA	LUPIN LTD	100 MG	10	TABLET SR	114.29	29636882.77	4.18%	4.18%	Y	11.43	11.43
27	VILDAMAC OD 100 MG TABLET SR 15	VILDAMAC	MACLEODS PHARMACEUTICALS PVT.LTD	100 MG	15	TABLET SR	141.43	33738630.12	4.78%	4.78%	Y	9.43	9.43
28	GLUPTAGREAT OD 100 MG TABLET SR 10	GLUPTAGREAT	MANKIND PHARMACEUTICALS LTD.	100 MG	10	TABLET SR	77.29	48103889.97	6.79%	6.79%	Y	7.78	7.78
29	VILACT 100 MG TABLET SR 10	VILACT	MANKIND PHARMACEUTICALS LTD.	100 MG	10	TABLET SR	107.14	1365463.48	0.19%	0.19%	N	10.71	
30	ZUKANORIM 100 MG TABLET SR 10	ZUKANORIM	MANKIND PHARMACEUTICALS LTD.	100 MG	10	TABLET SR	70.71	23262105.09	3.28%	3.28%	Y	7.07	7.07
31	VILDABLIS 100 MG TABLET SR 10	VILDABLIS	MED MANOR ORGANICS PVT.LTD.	100 MG	10	TABLET SR	85.71	24063.45	0.00%	0.00%	N	8.57	
32	VIDAGLO OD 100 MG TABLET SR 10	VIDAGLO	MEDLEY PHARMACEUTICALS	100 MG	10	TABLET SR	92.86	5234796.78	0.74%	0.74%	N	9.29	
33	VILDAPRIDE OD 100 MG TABLET SR 10	VILDAPRIDE	MICRO LABS LTD	100 MG	10	TABLET SR	93.57	31019469.49	4.38%	4.38%	Y	9.36	9.36
34	VILPOWER OD 100 MG TABLET SR 15	VILPOWER	MICRO LABS LTD	100 MG	15	TABLET SR	140	14738209.38	2.08%	2.08%	Y	9.33	9.33
35	VILMUR OD 100 MG TABLET SR 15	VILMUR	OPISCIARE LIFESCIENCE PVT LTD	100 MG	15	TABLET SR	106.07	332577.47	0.08%	0.08%	N	7.07	

36	VILDAPRIME 100 MG TABLET SR 15	VILDAPRIME	PRIMUS REMEDIES PVT. LTD	100 MG	15	TABLET SR	117.86	2918685.04	0.41%	0.41%	N	7.88	
37	VILSURE 100 MG TABLET SR 15	VILSURE	SINSAN PHARMACEUTICALS	100 MG	15	TABLET SR	160.71	492254.73	0.07%	0.07%	N	10.71	
38	VILDASPEC 100 MG TABLET SR 10	VILDASPEC	SPECTRA THERAPEUTICS PVT. LTD.	100 MG	10	TABLET SR	74.65	1073433.41	0.15%	0.15%	N	7.47	
39	ENCELIN OD 100 MG TABLET SR 10	ENCELIN	TORRENT PHARMACEUTICALS LTD.	100 MG	10	TABLET SR	85.43	45685037.01	0.45%	0.45%	Y	8.04	8.04
40	TORGUP OD 100 MG TABLET SR 10	TORGUP	TORRENT PHARMACEUTICALS LTD.	100 MG	10	TABLET SR	86.32	30328917.27	4.26%	4.28%	Y	8.83	8.83
41	VILASON OD 100 MG TABLET SR 10	VILASON	UNISON PHARMACEUTICALS	100 MG	10	TABLET SR	42.86	1967874.04	0.28%	0.28%	N	4.29	
42	JALRA OD 100 MG TABLET SR 10	JALRA	USV PVT LTD	100 MG	10	TABLET SR	128.57						
43	D VILDALOG 100 MG TABLET SR 10	D VILDALOG	WOCKHARDT LTD	100 MG	10	TABLET SR	142.86	4013080.26	0.57%	0.57%	N	14.28	
44	VINGLYN 100 MG TABLET SR 10	VINGLYN	ZYDUS CADILA - ZHL	100 MG	10	TABLET SR	86.04	20574783.00	2.50%	2.90%	Y	8.60	8.60
		Rs. Per Tablet											
	Worked out Retail Price	10.57	Excluding GST										

416

Computation of Retail Price based on Nov. 2022 Data under Para 5 of DPCO, 2013 (Ex Patent/License Holders)

Each film coated tablet containing Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg	Number of Companies consisting of Market Share of 1% & Above	19
	Sum of MAT value considered for price calculation (in Lakhs)	29,903.22
	Sum of PTR per unit considered for price calculation	241.27
	Number of Packs considered	24
	Average PTR	10.05
	Add: 16% Retailer Margin	1.61
	Retail Price (without local taxes)	11.66
% Reduction with compared to Highest Price	27.85%	

Minimum Price (Rs.)	7.07
Maximum Price (Rs.)	13.93
Average of all considered (Rs.)	10.05
Retail Price (Rs.)	11.66

S.No.	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR	3.33,37,71,304	100%	M3			
								MAT(Rs.)	SKU wise MAT %	Brandwise MAT (ignoring 0% MAT)	Quality (Y/N) Y=Yes N=No	Price per unit (Rs.)	Price per unit (Rs.) Considered
1	4 DAPA 10 MG TABLET 10	4 DAPA	4 CARE LIFESCIENCE PVT LTD	10 MG	10	TABLET	85	934830	0.03%	0.03%	N	8.50	
2	4 DAPA M 10 MG TABLET 10	4 DAPA M	4 CARE LIFESCIENCE PVT LTD	10 MG	10	TABLET	100	17500	0.00%	0.00%	N	10.00	
3	BIOXIGA 10 MG TABLET 10	BIOXIGA	BIOS LAB PVT.LTD	10 MG	10	TABLET	102.85	1326952	0.04%	0.04%	N	10.29	
4	DAGUPACK 10 MG TABLET 10	DAGUPACK	KOYE PHARMACEUTICALS PVT. LTD.	10 MG	10	TABLET	99.29	5573743	0.17%	0.17%	N	9.93	
5	DAVID 10 MG TABLET 15	DAVID	MICRO LABS LTD	10 MG	15	TABLET	137.86	47157258	1.41%	1.41%	Y	9.19	9.19
6	DAMITA 10 MG TABLET 10	DAMITA	MACLEODS PHARMACEUTICALS PVT.LTD	10 MG	10	TABLET	105.43	101468002	3.04%	3.04%	Y	10.64	10.64
7	DAPA GOLD 10 MG TABLET 15	DAPA GOLD	HBC LIFESCIENCES PVT LTD	10 MG	15	TABLET	150	15468300	0.46%	0.46%	N	10.00	
8	DAPABEST 10 MG TABLET 10	DAPABEST	PANACEA BIOTEC LTD.	10 MG	10	TABLET	100	7767200	0.23%	0.23%	N	10.00	
9	DAPABITE 10 MG TABLET 10	DAPABITE	CORONA	10 MG	10	TABLET	117.07	111779622	3.35%	3.35%	Y	11.71	11.71
10	DAPABLESS 10 MG TABLET 10	DAPABLESS	JAGSONPAL PHARMACEUTICALS LTD	10 MG	10	TABLET	50	13550	0.00%	0.00%	N	5.00	
11	DAPABUS 10 MG TABLET 10	DAPABUS	MED MANUR ORGANICS PVT LTD.	10 MG	10	TABLET	90	915474	0.03%	0.03%	N	9.00	
12	DAPACARE 10 MG TABLET 10	DAPACARE	OCTALIFE PHARMACEUTICALS PVT.LTD	10 MG	10	TABLET	78.57	354979	0.01%	0.01%	N	7.86	
13	DAPACONIC 10 MG TABLET 15	DAPACONIC	LA RENON	10 MG	15	TABLET	181.07	3920166	0.12%	0.12%	N	12.07	
14	DAPACOSE 10 MG TABLET 10	DAPACOSE	JB CHEMICALS	10 MG	10	TABLET	94.25	42488799	1.27%	1.27%	Y	9.43	9.43
15	DAPADEL 10 MG TABLET 10	DAPADEL	CADELL HEALTH CARE PVT.LTD	10 MG	10	TABLET	92.14	3873186	0.12%	0.12%	N	9.21	
16	DAPADOT 10 MG TABLET 10	DAPADOT	HETERO HEALTHCARE LTD	10 MG	10	TABLET	203.57	285335	0.01%	0.01%	N	10.36	
17	DAPAEASE 10 MG TABLET 10	DAPAEASE	JUBILANT GENERICS LIMITED	10 MG	10	TABLET	203.57	1287789	0.04%	0.04%	N	10.36	
18	DAPAEASE V 10 MG TABLET SR 15	DAPAEASE V	JUBILANT GENERICS LIMITED	10 MG	15	TABLET SR	135	645705	0.02%	0.02%	N	9.00	
19	DAPAFOR 10 MG TABLET 10	DAPAFOR	ZUVENTUS HEALTHCARE LTD.	10 MG	10	TABLET	75	355350	0.01%	0.01%	N	7.50	
20	DAPAGAIN 10 MG TABLET 15	DAPAGAIN	SYSTOPIE LABORATORIES LTD-MEM	10 MG	15	TABLET	63.22	31005490	0.93%	0.93%	N	4.21	
21	DAPAGLYN 10 MG TABLET 15	DAPAGLYN	ZYDUS CADILA - ZHL	10 MG	15	TABLET	200.36	263520885	7.90%	7.90%	Y	13.36	13.36
22	DAPAGREAT 10 MG TABLET 15	DAPAGREAT	SINSAN PHARMACEUTICALS	10 MG	15	TABLET	142.14	1124045	0.03%	0.03%	N	9.48	
23	DAPAGZA 10 MG TABLET 15	DAPAGZA	EMCLURE PHARMACEUTICALS LTD	10 MG	15	TABLET	159.64	2131513	0.06%	0.06%	N	10.64	
24	DAPAHENZ 10 MG TABLET 15	DAPAHENZ	LA RENON	10 MG	15	TABLET	198.57	16044878	0.48%	0.48%	N	13.24	
25	DAPAKEX 10 MG TABLET 10	DAPAKEX	PRESCIA PHARMA	10 MG	10	TABLET	103.57	7815185	0.23%	0.23%	N	10.36	
26	DAPALEX 10 MG TABLET 10	DAPALEX	AJANTA PHARMA LTD	10 MG	10	TABLET	110.71	36685620	1.10%	1.12%	Y	11.07	11.07
27	DAPALEX 10 MG TABLET 15	DAPALEX	AJANTA PHARMA LTD	10 MG	15	TABLET	165.71	763592	0.02%	1.12%	Y	11.05	11.05
28	DAPAMAC 10 MG TABLET 10	DAPAMAC	MACLEODS PHARMACEUTICALS PVT.LTD	10 MG	10	TABLET	106.43	171471725	5.14%	5.14%	Y	10.64	10.64
29	DAPANORM 10 MG TABLET 10	DAPANORM	ALKEM LABORATORIES LTD.	10 MG	10	TABLET	125	258122125	7.74%	7.74%	Y	12.50	12.50

30	DAPANOVA 10 MG TABLET 15	DAPANOVA	WEDLEY PHARMACEUTICALS	10 MG	15	TABLET	140.71	48003677	1.44%	1.44%	Y	9.38	9.38
31	DAPANTA 10 MG TABLET 10	DAPANTA	AJANTA PHARMA LTD	10 MG	10	TABLET	38.4	23386	0.00%	0.00%	N	3.84	
32	DAPAONE 10 MG TABLET 10	DAPAONE	MSN LABORATORIES LTD	10 MG	10	TABLET	107.14	36276533	1.09%	1.09%	Y	10.71	10.71
33	DAPARAY 10 MG TABLET 10	DAPARAY	ICON LIFESCIENCES	10 MG	10	TABLET	75.71	1558228	0.05%	0.05%	N	7.57	
34	DAPARYL 10 MG TABLET 10	DAPARYL	INTAS PHARMACEUTICALS LTD	10 MG	10	TABLET	92.86	243338423	7.30%	7.30%	Y	9.29	9.29
35	DAPASACH 10 MG TABLET 10	DAPASACH	CIPLA LTD.	10 MG	10	TABLET	71.43	1327455	0.04%	0.04%	N	7.14	
36	DAPASAN 10 MG TABLET 14	DAPASAN	SANATRA HEALTH CARE PVT.LTD	10 MG	14	TABLET	150	104550	0.00%	0.00%	N	10.71	
37	DAPASIS 10 MG TABLET 10	DAPASIS	AKESISS PHARMA (P) LTD	10 MG	10	TABLET	109.07	10051261	0.30%	0.30%	N	10.91	
38	DAPASPEC 10 MG TABLET 10	DAPASPEC	SPECTRA THERAPEUTICS PVT. LTD.	10 MG	10	TABLET	96.43	2645653	0.08%	0.08%	N	9.64	
39	DAPATEN 10 MG TABLET 15	DAPATEN	BAL PHARMA	10 MG	15	TABLET	117.54	592402	0.02%	0.02%	N	7.84	
40	DAPATREND 10 MG TABLET 14	DAPATREND	ANTHEM BIOPHARMA PVT LTD	10 MG	14	TABLET	117.86	6667331	0.20%	0.20%	N	8.42	
41	DAPATURN 10 MG TABLET 10	DAPATURN	LUPIN LTD	10 MG	10	TABLET	103.27	52039990	1.56%	1.56%	Y	10.36	10.36
42	DAPAVAS 10 MG TABLET 10	DAPAVAS	VASU ORGANICS PVT.LTD	10 MG	10	TABLET	83.57	4346	0.00%	0.00%	N	8.36	
43	DAPAVEL 10 MG TABLET 10	DAPAVEL	INTAS PHARMACEUTICALS LTD	10 MG	10	TABLET	92.86	299142918	8.97%	8.97%	Y	9.29	9.29
44	DAPAXIGA 10 MG TABLET 14	DAPAXIGA	ZERICO LIFESCIENCES PVT.LTD	10 MG	14	TABLET	139.29	4597	0.00%	0.00%	N	9.95	
45	DAPAYES 10 MG TABLET 10	DAPAYES	ANAX LIFE SCIENCES PVT.LTD	10 MG	10	TABLET	103.57	104295	0.00%	0.00%	N	10.36	
46	DAPAZOL 10 MG TABLET 10	DAPAZOL	ALTRES BIODGENES PVT.LTD.	10 MG	10	TABLET	106.07	725564	0.02%	0.02%	N	10.61	
47	DAPIXA 10 MG TABLET 10	DAPIXA	TAS MED (INDIA) PRIVATE LTD.	10 MG	10	TABLET	110	1531060	0.05%	0.05%	N	11.00	
48	DAPLO 10 MG TABLET 10	DAPLO	DR. REDDYS LABORATORIES LTD	10 MG	10	TABLET	117.86	93094608	2.79%	2.79%	Y	11.79	11.79
49	DAPNAT 10 MG TABLET 30	DAPNAT	NATCO PHARMA LTD	10 MG	30	TABLET	417.86	44789578	1.34%	1.34%	Y	13.93	13.93
50	DAPRICA 10 MG TABLET 10	DAPRICA	APRICA HEALTHCARE PVT LTD	10 MG	10	TABLET	111.86	13393061	0.40%	0.40%	N	11.19	
51	DAXIGA 10 MG TABLET 10	DAXIGA	ACMEDIX PHARMA LLP	10 MG	10	TABLET	49.29	8428639	0.25%	0.25%	N	4.93	
52	DEPAJA 10 MG TABLET 10	DEPAJA	INDOCO REMEDIES LTD	10 MG	10	TABLET	82.14	3563644	0.11%	0.11%	N	8.21	
53	DEXIGLU 10 MG TABLET 10	DEXIGLU	FUSION HEALTHCARE PVT LTD	10 MG	10	TABLET	103.57	20679822	0.62%	0.62%	N	10.36	
54	DGSDN 10 MG TABLET 10	DGSDN	UNISON PHARMACEUTICALS	10 MG	10	TABLET	32.14	6141118	0.18%	0.18%	N	3.21	
55	DIABFLOZ 10 MG TABLET 10	DIABFLOZ	FINCURE PHARMACEUTICALS	10 MG	10	TABLET	82.15	2972811	0.09%	0.09%	N	8.22	
56	DIABIZ (BLUE) 10 MG TABLET 15	DIABIZ (BLUE)	BLUE CROSS LABORATORIES LTD	10 MG	15	TABLET	75	8471775	0.25%	0.25%	N	5.00	
57	DIFLUP 10 MG TABLET 10	DIFLUP	EVELTIS	10 MG	10	TABLET	110.71	889666	0.03%	0.03%	N	11.07	
58	DIFOZIN 10 MG TABLET 14	DIFOZIN	LINCOLN PHARMACEUTICALS LTD	10 MG	14	TABLET	149.29	83005	0.00%	0.00%	N	10.66	
59	DIMPRIDE 10 MG TABLET 10	DIMPRIDE	INDICHEMIE HEALTH SPECIALTIES PVT. LTD.	10 MG	10	TABLET	125	604125	0.02%	0.02%	N	12.50	
60	DINECA 10 MG TABLET 14	DINECA	APOSTLE REMEDIES	10 MG	14	TABLET	100	152200	0.00%	0.00%	N	7.14	
61	DIOSGLT 10 MG TABLET 15	DIOSGLT	DIOS LIFESCIENCES PRIVATE LIMITED	10 MG	15	TABLET	133.93	480541	0.01%	0.01%	N	8.93	
62	DIUTEN 10 MG TABLET 10	DIUTEN	WOCKHARDT LTD	10 MG	10	TABLET	102.57	87419	0.00%	0.00%	N	10.36	
63	DMBEST 10 MG TABLET 10	DMBEST	KEPLER HEALTH CARE	10 MG	10	TABLET	92.86	279880	0.01%	0.01%	N	9.29	
64	DPO 10 MG TABLET 10	DPO	RPG LIFE SCIENCES LTD.	10 MG	10	TABLET	85.71	1244081	0.04%	0.04%	N	8.57	
65	ELDAPA 10 MG TABLET 10	ELDAPA	EL-DORADO BIO-TECH PVT LTD	10 MG	10	TABLET	71.43	115431	0.00%	0.00%	N	7.14	
66	EMILDAP 10 MG TABLET 15	EMILDAP	EMCURE PHARMACEUTICALS LTD	10 MG	15	TABLET	159.64	14574334	0.44%	0.44%	N	10.64	
67	ESGEDAP 10 MG TABLET 14	ESGEDAP	EAST WEST PHARMA	10 MG	14	TABLET	145	769080	0.02%	0.02%	N	10.36	
68	FLOZIMAX 10 MG TABLET 15	FLOZIMAX	ALNICHE LIFE SCIENCES PVT.LTD	10 MG	15	TABLET	139.29	3557327	0.11%	0.11%	N	9.29	
69	FLOZIPIA 10 MG TABLET 10	FLOZIPIA	WALLACE PHARMACEUTICALS LTD.	10 MG	10	TABLET	100	1453900	0.04%	0.04%	N	10.00	
70	GLIFDAPA 10 MG TABLET 10	GLIFDAPA	CMR LIFE SCIENCES	10 MG	10	TABLET	96.43	18611	0.00%	0.00%	N	9.64	
71	GLIFOPRIME 10 MG TABLET 10	GLIFOPRIME	PRIMUS REMEDIES PVT LTD	10 MG	10	TABLET	103.57	3919917	0.12%	0.12%	N	10.36	
72	GLUCRETA 10 MG TABLET 10	GLUCRETA	TORRENT PHARMACEUTICALS LTD.	10 MG	10	TABLET	89.25	166362546	4.99%	4.99%	Y	8.93	8.93
73	GLUFLOZIN 10 MG TABLET 15	GLUFLOZIN	ARISTO PHARMACEUTICALS PVT.LTD	10 MG	15	TABLET	107.14	36912087	1.11%	1.11%	Y	7.14	7.14
74	GLUXIT 10 MG TABLET 10	GLUXIT	ERIS LIFESCIENCES LTD	10 MG	10	TABLET	103.57	313212976	9.40%	9.40%	Y	10.36	10.36
75	JODAPA 10 MG TABLET 15	JODAPA	JARUN PHARMACEUTICALS	10 MG	15	TABLET	107.14	1386294	0.04%	0.04%	N	7.14	
76	JUSTOZA 10 MG TABLET 10	JUSTOZA	MANKIND PHARMACEUTICALS LTD.	10 MG	10	TABLET	70.71	53778137	1.61%	1.67%	Y	7.07	7.07
77	JUSTOZA 10 MG TABLET 15	JUSTOZA	MANKIND PHARMACEUTICALS LTD.	10 MG	15	TABLET	106.07	2030816	0.06%	1.67%	Y	7.07	7.07
78	LVEFFECT 10 MG TABLET 15	LVEFFECT	ABBOTT HEALTHCARE PVT. LTD	10 MG	15	TABLET	160.71	1728757	0.05%	0.05%	N	10.71	
79	MDAPA 10 10 MG TABLET 10	MDAPA 10	SINSAN PHARMACEUTICALS	10 MG	10	TABLET	96.43	2914404	0.09%	0.10%	N	9.64	
80	MDAPA 10 10 MG TABLET 15	MDAPA 10	SINSAN PHARMACEUTICALS	10 MG	15	TABLET	96.43	423521	0.01%	0.10%	N	6.43	
81	MYODA 10 MG TABLET 10	MYODA	ERIS LIFESCIENCES LTD	10 MG	10	TABLET	113.93	9282054	0.28%	0.28%	N	11.39	

711-418

82	OPSICA 10 MG TABLET 15	OPSICA	OPSCARE LIFESCIENCE PVT LTD	10 MG	15	TABLET	150	1094850	0.03%	0.03%	N	10.00	
83	OZODAP 10 MG TABLET 15	OZODAP	OZONE PHARMACEUTICALS	10 MG	15	TABLET	53.57	18375	0.00%	0.00%	N	3.57	
84	SGLTD 10 MG TABLET 10	SGLTD	MANKIND PHARMACEUTICALS LTD.	10 MG	10	TABLET	70.71	26001976	0.78%	0.78%	N	7.07	
85	SHIDAPA 10 MG TABLET 20	SHIDAPA	SHINE PHARMACEUTICALS LTD	10 MG	10	TABLET	85.71	2486	0.00%	0.00%	N	8.57	
86	SINKIGA 10 10 MG TABLET 10	SINKIGA 10	SINSAN PHARMACEUTICALS	10 MG	10	TABLET	96.43	74155	0.00%	0.00%	N	9.64	
87	SUGAFLO 10 MG TABLET 15	SUGAFLO	LLOYD HEALTHCARE PVT.LTD	10 MG	15	TABLET	160.72	16680325	0.50%	0.50%	N	10.71	
88	SWITDAPA 10 MG TABLET 10	SWITDAPA	AKUMENTIS HEALTHCARE LTD	10 MG	10	TABLET	85	8816625	0.26%	0.26%	N	8.50	
89	T2C 10 MG TABLET 15	T2C	IPCA LABORATORIES PVT LTD.	10 MG	15	TABLET	182.14	22025097	0.66%	0.66%	N	12.14	
90	UDAPA 10 MG TABLET 10	UDAPA	USV PVT LTD	10 MG	10	TABLET	94.29	372927356	11.19%	11.19%	Y	9.43	9.43
91	VIVADAPA 10 MG TABLET 10	VIVADAPA	MITOCH PHARMA PVT LTD	10 MG	10	TABLET	100	14937200	0.43%	0.43%	N	10.00	
92	VOAGE 10 MG TABLET 10	VOAGE	ALEMBIC LTD	10 MG	10	TABLET	77.43	93087872	2.79%	2.79%	Y	7.74	7.74
93	XGLET 10 MG TABLET 10	XGLET	ELINDR PHARMA	10 MG	10	TABLET	140	238140	0.01%	0.01%	N	14.00	
94	ZANELLA 10 MG TABLET 10	ZANELLA	CADOMED PHARMACEUTICALS INDIA PVT.LTD	10 MG	10	TABLET	79.07	1733026	0.05%	0.05%	N	7.91	
95	ZINODAP 10 MG TABLET 10	ZINODAP	WOCKHARDT LTD	10 MG	10	TABLET	113.57	18009423	0.54%	0.54%	N	11.36	
96	ZUCAPRIDE 10 MG TABLET 15	ZUCAPRIDE	MICRO LABS LTD	10 MG	15	TABLET	137.86	101866876	3.06%	3.06%	Y	9.19	9.19
		Rs. Per Tablet											
	Worked out Retail Price	11.66	Excluding GST										